Femasys Inc. Files 8-K Report
Ticker: FEMY · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1339005
| Field | Detail |
|---|---|
| Company | Femasys Inc (FEMY) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $9,800,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Femasys Inc. filed a routine 8-K, mostly financial statements and exhibits.
AI Summary
On December 23, 2025, Femasys Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided excerpt. The company is incorporated in Delaware and headquartered in Suwanee, Georgia.
Why It Matters
This filing indicates Femasys Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard current report and does not disclose any new material events, risks, or financial changes.
Key Numbers
- 001-40492 — SEC File Number (Identifies the company's filing with the SEC.)
- 11-3713499 — EIN (Employer Identification Number for Femasys Inc.)
Key Players & Entities
- Femasys Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Suwanee, Georgia (location) — Principal Executive Offices
- December 23, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the filing's item information.
When was this 8-K report filed?
This 8-K report was filed on December 23, 2025.
In which state is Femasys Inc. incorporated?
Femasys Inc. is incorporated in Delaware.
What is the principal executive office address for Femasys Inc.?
The principal executive offices are located at 3950 Johns Creek Court, Suite 100, Suwanee, Georgia 30024.
Does this filing report any specific material events?
Based on the provided excerpt, the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' with no specific material events detailed.
Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-12-23 16:07:57
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share FEMY The Nasdaq Stock Mar
- $9,800,000 — ng an aggregate offering price of up to $9,800,000, pursuant to the Equity Distribution Ag
Filing Documents
- ef20061695_8k.htm (8-K) — 33KB
- ef20061695_ex5-1.htm (EX-5.1) — 13KB
- image01.jpg (GRAPHIC) — 3KB
- 0001140361-25-046546.txt ( ) — 185KB
- femy-20251223.xsd (EX-101.SCH) — 4KB
- femy-20251223_lab.xml (EX-101.LAB) — 22KB
- femy-20251223_pre.xml (EX-101.PRE) — 16KB
- ef20061695_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On December 23, 2025, Femasys Inc. (the " Company ") filed a prospectus supplement for the offer and sale of shares (the " Shares ") of its common stock, par value $0.001 per share (the " Common Stock "), having an aggregate offering price of up to $9,800,000, pursuant to the Equity Distribution Agreement (the " Equity Distribution Agreement "), dated July 1, 2022, with Piper Sandler & Co. (the " Sales Agent ") under which the Company may offer and sell Shares, from time to time at its sole discretion, through its Sales Agent. Pursuant to the Equity Distribution Agreement, sales of the Shares will be made under the Company's previously filed and effective Registration Statement on Form S-3 (File No. 333-288527) and an applicable prospectus supplement, by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Subject to the terms and conditions of the Equity Distribution Agreement, the Sales Agent may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended. The Sales Agent will use commercially reasonable efforts to sell the Shares from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The foregoing description of the Equity Distribution Agreement is not complete and is qualified in its entirety by reference to the full text of the Equity Distribution Agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or
Financial Statements and Exhibits
Financial Statements and Exhibits. The following exhibits are filed as part of this report. Exhibit Number Description 5.1 Opinion of Dechert LLP 10.1 Equity Purchase Agreement dated July 1, 2022, between Femasys Inc. and Piper Sandler & Co. (incorporated by reference to Exhibit 1.2 of the Company's Registration Statement on Form S-3 (File No. 333-266001) filed July 1, 2022) 23.1 Consent of Dechert LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Femasys Inc. Date: December 23, 2025 By: /s/ Kathy Lee-Sepsick Name: Kathy Lee-Sepsick Title: Chief Executive Officer